Monoclonal antibodies that neutralize anthrax toxins

US9580492B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Zhaochun Chen · Potomac, US
• Robert H. Purcell · Boyds, US
• Suzanne U. Emerson · Rockville, US
• Stephen H. Leppla · Bethesda, US
• Mahtab Moayeri · Bethesda, US

Key dates

• Filing date: Jan 13, 2015
• Grant date: Feb 28, 2017
• Expiry date: Jan 13, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2469/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.